Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma |
| |
| Institution: | 1. Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy;2. Unit of Clinical Epidemiology, University of Turin, Turin, Italy;3. Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy;4. Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA;5. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA;6. Department of Hematology, St Olavs Hospital/Norwegian University of Science and Technology (NTNU) and KG Jebsen Myeloma Research Center, Trondheim, Norway;7. HOVON Data Center, Erasmus MC–Clinical Trial Center, Rotterdam, Netherlands;8. Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy;9. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;10. Department of Hematology, VU University Medical Center, Amsterdam, Netherlands;11. Division of Bone Marrow Transplant, Winship Cancer Institute, Atlanta, GA, USA;12. Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, GA, USA;13. Department of Clinical Hematology and Bone Marrow Transplant, Alfred Health–Monash University, Melbourne, VIC, Australia;14. Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece;15. Faculty of Medicine, and Department of Haematooncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic;p. “Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;q. Dana-Farber Cancer Institute, Boston, MA, USA;r. Department of Hematology, Erasmus MC, Rotterdam, Netherlands;s. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA;1. Department of Pharmacy, University of Sao Paulo, Sao Paulo, Brazil;2. Department of Clinical and Experimental Oncology, Division of Hematology, Federal University of Sao Paulo, Sao Paulo, Brazil;1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia;2. Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia;3. Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;4. Department of Medicine, University of Melbourne, Parkville, Australia;5. Victorian Infectious Diseases Service, Doherty Institute for Infection and Immunity, Australia |
| |
| Abstract: | Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world. Front line treatment has shifted but ultimately has landed on a bortezomib-based combination therapy. Carfilzomib is a next-generation proteasome inhibitor shown to improve both progression-free and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd). Given the favorable response rates seen in phase II trials treating newly diagnosed myeloma, this combination is listed as a viable option for upfront treatment. This systematic review compares pharmacologic properties, clinical efficacy, and toxicities of carfilzomib- and bortezomib-based regimens. |
| |
| Keywords: | myeloma treatment carfilzomib bortezomib toxicity |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
